AZ3391

Item no.	HY-144874-50mg
Manufacturer	MedChem Express
CASRN	2756333-42-1
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.03
Formula	C23H27FN6O2
Citations	[1]Martin John Packer, et al. Quinoxaline derivatives as anti-cancer drugs. Patent WO2021260092A1.
Smiles	O=C(C1=NC(C)=C(N2CCN(CC3=C(F)C4=C(N=C(CC)C(N4)=O)C=C3)CC2)C=C1)NC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	PARP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	438.50
Product Description	AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23)[1].
Manufacturer - Research Area	Cancer; Neurological Disease
Solubility	DMSO : 16.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-144874-50mg-safety-datasheet.pdf